Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07284420 · ClinicalTrials.gov registry record · Phase 2
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
A Phase 2 study of Myasthenia Gravis and Generalized Myasthenia Gravis, sponsored by argenx.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 5
- Study locations
NCT07284420: Recruiting Phase 2 study of Myasthenia Gravis and Generalized Myasthenia Gravis, sponsored by argenx.
NCT07284420 is a Phase 2 study of Myasthenia Gravis and Generalized Myasthenia Gravis that is actively recruiting participants, run by argenx. The registered enrollment target is 70 participants, below the 189-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (63% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07284420, a Phase 2 study of Myasthenia Gravis and Generalized Myasthenia Gravis, is actively recruiting participants, sponsored by argenx.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study is part of the ADAPT Forward platform study (NCT07294170). ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects and improve their quality of life. The aim of this ISA1 is to evaluate the safety and therapeutic relevance of empasiprubart as add-on therapy to efgartigimod in participants with AChR-Ab seropositive generalized myasthenia gravis. The ADAPT Forward master protocol is registered on https://clinicaltrials.gov/study/NCT07294170
Conditions Studied
Interventions
- BIOLOGICAL Efgartigimod IV
- BIOLOGICAL Empasiprubart IV
Study Locations (5)
California
- Profound Research LLC - Carlsbad - Carlsbad
Florida
- Visionary Investigators Network - Miami
New York
- Dent Neurologic Institute - Amherst - Amherst
Tennessee
- Erlanger Health System - Chattanooga
Texas
- National Neuromuscular Research Institute - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2025-12-19 |
| Est. Completion | 2028-03-07 |
| Phase | Phase 2 |
What NCT07284420 shows while recruiting
NCT07284420 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 189-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (63% lower).
The record links to 6 conditions, with Myasthenia Gravis appearing as the primary indexed condition, and to 2 interventions - of which Efgartigimod IV is the first listed.
NCT07284420 lists 5 locations in 5 states (California, Florida, New York).
Frequently Asked Questions
What is clinical trial NCT07284420 about?
NCT07284420 is a clinical study titled "ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod". This study is part of the ADAPT Forward platform study (NCT07294170). ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects an...
What is the current status of trial NCT07284420?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2025-12-19. Estimated completion is 2028-03-07.
What conditions does trial NCT07284420 study?
This clinical trial studies the following conditions: Myasthenia Gravis, Generalized Myasthenia Gravis, gMG, Generalized Myasthenia Gravis (gMG), MG.
What interventions are being tested in trial NCT07284420?
The interventions under investigation include: Efgartigimod IV (BIOLOGICAL), Empasiprubart IV (BIOLOGICAL).
Who is sponsoring clinical trial NCT07284420?
This trial is sponsored by argenx, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07284420 being conducted?
This trial has 5 study locations across California, Florida, New York, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myasthenia Gravis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07284420's enrollment target sits among peer trials
70 19th of 32 higher than 13 of 32 other Myasthenia Gravis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myasthenia Gravis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
RECRUITING · Phase 2
-
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
RECRUITING · Phase 2
-
A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
RECRUITING · Phase 2
-
BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis
COMPLETED · Phase 2
-
A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
COMPLETED · Phase 2
-
A Study of RVT-1401 in Myasthenia Gravis (MG) Patients
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI